Accessibility Menu
Defence Therapeutics logo

Defence Therapeutics(OTC) DTCFF

Market Cap$22.25MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-88%
5 Year-94%
1 Year-43%
1 Month-15%
$0.29
+8.54%
+0.02Today
Defence Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 0.292026-07-27
Defence Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-16.11%USD 0.352026-07-17
1 month-14.92%USD 0.352026-06-26
3 month-25.27%USD 0.392026-04-28
Year to date-47.35%USD 0.562025-12-31
1 year-43.17%USD 0.522025-07-03
3 year-86.09%USD 2.112023-07-28
5 year-93.75%USD 4.702021-07-19
Since inception-88.26%USD 2.502021-05-18

Defence Therapeutics Financials at a Glance

Market Cap

$22.25MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$0.00

Net Income (TTM)

-CA$6.19M

EPS (TTM)

-$0.08

P/E Ratio

-3.63

Dividend

$0.00

Beta (Volatility)

0.02 (Low)

Price

$0.29

Volume

10,410

Open

$0.35

Previous Close

$0.29

Daily Range

$0.28 - $0.35

52-Week Range

$0.25 - $0.78

Estimated Earnings Date

Jun 21, 2022

DTCFF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Defence Therapeutics

Defence Therapeutics Inc. is a biotechnology company focused on developing innovative drug enhancement platforms aimed at improving the efficacy and safety of biological pharmaceuticals. The company specializes in treatments for cancer and infectious diseases through its proprietary Accum technology.

Products and Services
  • Antibody drug conjugates targeting various cancers
  • AccuTOX program for solid T-cell lymphoma, breast cancer, and melanoma
  • Dendritic Cell cancer vaccines and mRNA vaccination programs
Growth Outlook
  • Strong pipeline with multiple preclinical studies underway
  • Focus on expanding vaccine programs for infectious diseases
  • Potential partnerships to enhance research and development capabilities
Financial Highlights
  • Recent quarterly net income of -$2.97 million, reflecting ongoing R&D investments
  • Cash and cash equivalents of $2.96 million as of March 31, 2026
  • Current ratio of 3.37, indicating strong liquidity position
Defence Therapeutics Inc. is positioned in the healthcare sector, specifically within the medical pharmaceuticals industry. The company has made significant strides in developing its product offerings, particularly in the realm of cancer treatment and vaccine development. The Accum technology platform is central to its strategy, enhancing the effectiveness of existing therapies. The growth outlook remains promising, with a robust pipeline of products in various stages of development. The focus on innovative solutions for cancer and infectious diseases aligns with increasing global healthcare needs. Additionally, the potential for strategic partnerships could further accelerate growth and expand market reach. Financially, Defence Therapeutics has been investing heavily in research and development, which is reflected in its recent net income figures. Despite the losses, the company maintains a solid liquidity position, as indicated by its current ratio. This financial stability allows for continued investment in its innovative projects, positioning the company for future growth in a competitive market.
AI Generated • Jul 18, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Sébastien Plouffe

Website

www.defencetherapeutics.com

Headquarters

Vancouver, BC H4S1Z9, CA

DTCFF Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-1661.38%

Return on Capital

-594.06%

Return on Assets

-67.17%

Earnings Yield

-27.55%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$22.25MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

75.79M

Volume

10.41K

Avg. Volume

8.01K

Financials (TTM)

Gross Profit

-CA$34.98K

Operating Income

-CA$4.44M

EBITDA

-CA$3.40M

Operating Cash Flow

-CA$4.71M

Capital Expenditure

CA$808.83K

Free Cash Flow

-CA$3.73M

Cash & ST Invst.

CA$2.96M

Total Debt

CA$1.57M

Defence Therapeutics Performance Analysis

Defence Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30CAD 0N/A
20232023-06-30CAD 0N/A
20242024-06-30CAD 0N/A
20252025-06-30CAD 0N/A
Defence Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-06-30N/A
Q12025-09-30N/A
Q22025-12-31N/A
Q32026-03-31N/A
Defence Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30CAD -0.16N/A
20232023-06-30CAD -0.13-20.8%
20242024-06-30CAD -0.2271.4%
20252025-06-30CAD -0.05-76.8%
Defence Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-06-3019.2%
Q12025-09-3017.9%
Q22025-12-31-114.1%
Q32026-03-31-83.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2026YOY CHG

Revenue

CA$0.00

N/A

Gross Profit

-CA$9.45K

N/A

Gross Margin

0.00%

N/A

Market Cap

$22.25MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$17.12K

N/A

Employees

1,300

N/A

Net Income

-CA$2.97M

-211.9%

EBITDA

-CA$1.41M

-65.7%

Quarterly Fundamentals

Name
Q3 2026YOY CHG

Total Cash

CA$2.96M

+42.4%

Total Debt

CA$1.57M

+12.6%

Accounts Receivable

CA$316.00K

+259.9%

Inventory

CA$0.00

N/A

Long Term Debt

CA$1.57M

N/A

Short Term Debt

CA$0.00

-100.0%

Return on Assets

-67.17%

N/A

Return on Invested Capital

-53.54%

N/A

Free Cash Flow

-CA$1.59M

+20.2%

Operating Cash Flow

-CA$1.59M

+20.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PVCTProvectus Biopharmaceuticals, Inc.
$0.06-0.17%
FNCHFinch Therapeutics Group, Inc.
$9.60-3.71%
MBXBFMicrobix Biosystems Inc.
$0.22+0.00%
SEOVFSernova Corp.
$0.08-3.58%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.20-0.01%
NOKNokia
$8.91-0.04%
JBLUJetBlue Airways
$6.00+0.10%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.12-0.02%

Questions About DTCFF

What is the current price of Defence Therapeutics?

Defence Therapeutics is trading at $0.29 per share.

What is the 52-week range for Defence Therapeutics?

Over the past 52 weeks, Defence Therapeutics has traded between $0.25 and $0.78.

How much debt does Defence Therapeutics have?

As of the most recent reporting period, Defence Therapeutics reported total debt of CA$1.12M.

How much cash does Defence Therapeutics have on hand?

Defence Therapeutics reported CA$2.12M in cash and cash equivalents in its most recent financial results.

What is Defence Therapeutics’s dividend yield?

Defence Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services